{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:05:16Z","timestamp":1789506316158,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,6,13]],"date-time":"2017-06-13T00:00:00Z","timestamp":1497312000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s40259-017-0232-7","type":"journal-article","created":{"date-parts":[[2017,6,13]],"date-time":"2017-06-13T08:01:18Z","timestamp":1497340878000},"page":"357-367","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial"],"prefix":"10.1007","volume":"31","author":[{"given":"Dae Hyun","family":"Yoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Hee","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Cheol","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slawomir","family":"Jeka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Fidencio Cons","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Hrycaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Wiland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco G.","family":"Medina-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Shesternya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiao","family":"Radominski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Stanislav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volodymyr","family":"Kovalenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Hyuk","family":"Sheen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leysan","family":"Myasoutova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mie Jin","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Yoon","family":"Choe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Joon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,13]]},"reference":[{"key":"232_CR1","doi-asserted-by":"crossref","unstructured":"Lopez-Olivo MA, Amezaga Urruela M, McGahan L, et al. Rituximab for rheumatoid arthritis. Cochrane Database Syst Rev 2015;(1):CD007356.","DOI":"10.1002\/14651858.CD007356.pub2"},{"key":"232_CR2","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"JC Edwards","year":"2004","unstructured":"Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350:2572\u201381.","journal-title":"N Engl J Med"},{"key":"232_CR3","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","volume":"54","author":"SB Cohen","year":"2006","unstructured":"Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793\u2013806.","journal-title":"Arthritis Rheum"},{"key":"232_CR4","unstructured":"European Medicines Agency. European public assessment report for Truxima. 2017. \n                        http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/004112\/WC500222696.pdf\n                        \n                    . Accessed 27 Mar 2017."},{"key":"232_CR5","first-page":"566","volume":"76","author":"DH Yoo","year":"2016","unstructured":"Yoo DH, Suh C, Shim SC, et al. A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2016;76:566\u201370.","journal-title":"Ann Rheum Dis"},{"key":"232_CR6","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.3899\/jrheum.120573","volume":"39","author":"EC Keystone","year":"2012","unstructured":"Keystone EC, Cohen SB, Emery P, et al. Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study. J Rheumatol. 2012;39:2238\u201346.","journal-title":"J Rheumatol"},{"key":"232_CR7","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3899\/jrheum.090442","volume":"37","author":"PJ Mease","year":"2010","unstructured":"Mease PJ, Cohen S, Gaylis NB, et al. Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial. J Rheumatol. 2010;37:917\u201327.","journal-title":"J Rheumatol"},{"key":"232_CR8","doi-asserted-by":"crossref","first-page":"R80","DOI":"10.1186\/ar4521","volume":"16","author":"J Wendler","year":"2014","unstructured":"Wendler J, Burmester GR, S\u00f6rensen H, et al. Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patients. Arthritis Res Ther. 2014;16:R80.","journal-title":"Arthritis Res Ther"},{"key":"232_CR9","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/ard.2010.144998","volume":"70","author":"MH Buch","year":"2011","unstructured":"Buch MH, Smolen JS, Betteridge N, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:909\u201320.","journal-title":"Ann Rheum Dis"},{"key":"232_CR10","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1093\/rheumatology\/ker106a","volume":"50","author":"M Bukhari","year":"2011","unstructured":"Bukhari M, Abernethy R, Deighton C, et al. BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis. Rheumatology (Oxford). 2011;50:2311\u20133.","journal-title":"Rheumatology (Oxford)"},{"key":"232_CR11","first-page":"w13073","volume":"140","author":"J Dudler","year":"2010","unstructured":"Dudler J, Finckh A, Kyburz D, et al. Swiss consensus statement: Recommendations for optimising re-treatment with MabThera (rituximab) in rheumatoid arthritis. Swiss Med Wkly. 2010;140:w13073.","journal-title":"Swiss Med Wkly"},{"key":"232_CR12","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.berh.2011.10.005","volume":"25","author":"MJ Leandro","year":"2011","unstructured":"Leandro MJ, Becerra-Fernandez E. B-cell therapies in established rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2011;25:535\u201348.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"232_CR13","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1136\/annrheumdis-2013-203480","volume":"73","author":"X Mariette","year":"2014","unstructured":"Mariette X, Rouanet S, Sibilia J, et al. Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial. Ann Rheum Dis. 2014;73:1508\u201314.","journal-title":"Ann Rheum Dis"},{"key":"232_CR14","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1136\/ard.2009.119933","volume":"69","author":"P Emery","year":"2010","unstructured":"Emery P, Deodhar A, Rigby WF, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab\u2019s Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis. 2010;69:1629\u201335.","journal-title":"Ann Rheum Dis"},{"key":"232_CR15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/ard.2010.137703","volume":"70","author":"PP Tak","year":"2011","unstructured":"Tak PP, Rigby WF, Rubbert-Roth A, et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis. 2011;70:39\u201346.","journal-title":"Ann Rheum Dis"},{"key":"232_CR16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2007.083188","volume":"68","author":"C Salliot","year":"2009","unstructured":"Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis. 2009;68:25\u201332.","journal-title":"Ann Rheum Dis"},{"key":"232_CR17","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3899\/jrheum.150051","volume":"42","author":"RF Vollenhoven van","year":"2015","unstructured":"van Vollenhoven RF, Fleischmann RM, Furst DE, et al. Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years. J Rheumatol. 2015;42:1761\u20136.","journal-title":"J Rheumatol"},{"key":"232_CR18","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1002\/art.27555","volume":"62","author":"JE Gottenberg","year":"2010","unstructured":"Gottenberg JE, Ravaud P, Bardin T, et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum. 2010;62:2625\u201332.","journal-title":"Arthritis Rheum"},{"key":"232_CR19","unstructured":"European Medicines Agency. Rituximab. Summary of product characteristics. 2015. \n                        http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000165\/WC500025821.pdf\n                        \n                    . Accessed 21 Feb 2017."},{"key":"232_CR20","first-page":"e413","volume":"164","author":"F Conti","year":"2013","unstructured":"Conti F, Ceccarelli F, Massaro L, et al. Biological therapies in rheumatic diseases. Clin Ter. 2013;164:e413\u201328.","journal-title":"Clin Ter"},{"key":"232_CR21","first-page":"911","volume":"2","author":"AP Tsiakalos","year":"2008","unstructured":"Tsiakalos AP, Avgoustidis NK, Moutsopoulos HM. Rituximab therapy in Greek patients with rheumatoid arthritis. Biologics. 2008;2:911\u20136.","journal-title":"Biologics"},{"key":"232_CR22","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.3109\/10428194.2013.843090","volume":"55","author":"A Silva da","year":"2014","unstructured":"da Silva A, Kronthaler U, Koppenburg V, et al. Target-directed development and preclinical characterization of the proposed biosimilar rituximab GP2013. Leuk Lymphoma. 2014;55:1609\u201317.","journal-title":"Leuk Lymphoma"},{"key":"232_CR23","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1517\/14712598.2013.787064","volume":"13","author":"EM Vital","year":"2013","unstructured":"Vital EM, Kay J, Emery P. Rituximab biosimilars. Expert Opin Biol Ther. 2013;13:1049\u201362.","journal-title":"Expert Opin Biol Ther"},{"issue":"Suppl 10","key":"232_CR24","first-page":"1635","volume":"68","author":"D-H Yoo","year":"2016","unstructured":"Yoo D-H, Majstorovic L, Kasay A, et al. Efficacy and safety of CT-P10, rituximab biosimilar candidate, and innovator rituximab in patients with rheumatoid arthritis: results from Phase 3 randomized controlled trial over 24 weeks. Arthritis Rheumatol. 2016;68(Suppl 10):1635.","journal-title":"Arthritis Rheumatol"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-017-0232-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-017-0232-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-017-0232-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,8]],"date-time":"2017-08-08T06:45:10Z","timestamp":1502174710000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-017-0232-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,13]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["232"],"URL":"https:\/\/doi.org\/10.1007\/s40259-017-0232-7","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,13]]}}}